Jefferies Warns AstraZeneca's Wainua Trial Failure Damages Credibility More Than Valuation
AstraZeneca faced a significant credibility hit after its drug Wainua failed in clinical trials, according to Jefferies. The stock dropped 9%, outpacing the financial impact of the failure itself due to investor concerns over management's reliability.
Topics: AstraZeneca Jefferies analysis stock impact Wainua drug failure